Deborah White

22PUBLICATIONS
50CO-AUTHORS
Cancer cell biologyMolecular targetsHaematological tumoursBiologically active moleculesApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Jun 11, 2026
Direct measurement of in vivo BCR::ABL1 kinase inhibition reveals stronger potency of asciminib as compared with imatinib and nilotinib.

|Sep 27, 2025
Lipid Storage and Therapy Resistance in Chronic Myeloid Leukaemia: A Novel Perspective on Targeting Metabolic Vulnerabilities.

Molly Tolland, David M Ross, Deborah White

|Apr 17, 2025
T-cell acute lymphoblastic leukaemia: subtype prevalence, clinical outcome, and emerging targeted treatments.

Maxim Buckley, David T Yeung, Deborah L White

|Jun 07, 2024
Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy.

Laura N Eadie, Elias Lagonik, Elyse C Page

|Oct 14, 2023
Reproducible Bioinformatics Analysis Workflows for Detecting <i>IGH</i> Gene Fusions in B-Cell Acute Lymphoblastic Leukaemia Patients.

Ashlee J Thomson, Jacqueline A Rehn, Susan L Heatley

|Sep 11, 2023
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib.

Chung H Kok, Verity A Saunders, Phuong Dang

Pageof 4

Frequent Collaborators

9 joint publications

Susan L Heatley

8 joint publications

Barbara J McClure

7 joint publications

Laura N Eadie

6 joint publications

David Yeung